{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:35:14Z","timestamp":1778564114870,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.antiviral.2019.104678","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:25:23Z","timestamp":1576610723000},"page":"104678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Structure-activity relationships of fluorene compounds inhibiting HCV variants"],"prefix":"10.1016","volume":"174","author":[{"given":"Hee Sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngsu","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaegon","family":"Mun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changdev G.","family":"Gadhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ae Nim","family":"Pae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyochang","family":"Keum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Key","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104678_bib1","series-title":"Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating Hcv-Related Disease","author":"Kim","year":"2019"},{"key":"10.1016\/j.antiviral.2019.104678_bib2","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/srep04765","article-title":"Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA","volume":"4","author":"Ascher","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104678_bib3","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1021\/acs.biochem.7b00212","article-title":"Overall structural model of NS5A protein from hepatitis C virus and modulation by mutations confering resistance of virus replication to cyclosporin A","volume":"56","author":"Badillo","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2019.104678_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejmech.2015.06.033","article-title":"Novel benzidine and diamino fluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors","volume":"101","author":"Bae","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104678_bib5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104678_bib6","series-title":"CompuSyn for Drug Combinations and for General Dose-Effect Analysis, Software and User's Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values","author":"Chou","year":"2005"},{"key":"10.1016\/j.antiviral.2019.104678_bib7","series-title":"Discovery Studio Modeling Environment, Release 2018","author":"Dassault Systems BIOVIA","year":"2018"},{"key":"10.1016\/j.antiviral.2019.104678_bib8","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104678_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104678_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-Acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104678_bib11","first-page":"267","article-title":"HCV NS5A: a multifunctional regulator of cellular pathways and virus replication","author":"He","year":"2006","journal-title":"Hepat. C Viruses: Genomes Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.104678_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2007.01.042","article-title":"Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?","volume":"364","author":"Huang","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104678_bib13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1021\/jm4013104","article-title":"Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound","volume":"57","author":"Kazmierski","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104678_bib14","first-page":"1843","volume":"vol. 7","author":"Khullar","year":"2015"},{"key":"10.1016\/j.antiviral.2019.104678_bib15","article-title":"Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104678_bib16","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1128\/JVI.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104678_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pro.2456","article-title":"The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors","volume":"23","author":"Lambert","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.antiviral.2019.104678_bib18","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104678_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104678_bib20","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.02352-08","article-title":"Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus","volume":"83","author":"Love","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104678_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104678_bib22","doi-asserted-by":"crossref","first-page":"40835","DOI":"10.1074\/jbc.M404761200","article-title":"Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A","volume":"279","author":"Penin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.104678_bib23","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1128\/JVI.00891-09","article-title":"Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes","volume":"83","author":"Phan","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104678_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tim.2019.01.001","article-title":"Hepatitis C virus","volume":"27","author":"Pietschmann","year":"2019","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2019.104678_bib25","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2019.104678_bib26","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1002\/j.1460-2075.1989.tb08565.x","article-title":"Identification of four conserved motifs among the RNA-dependent polymerase encoding elements","volume":"8","author":"Poch","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.104678_bib27","first-page":"47","article-title":"Recommendations for the treatment of hepatitis C in 2017","volume":"3","author":"Polish Group of Experts for","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104678_bib28","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1038\/s41598-017-04931-y","article-title":"Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients","volume":"7","author":"Raj","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104678_bib29","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104678_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.antiviral.2019.104678_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates : Rev. Comment. Antimicrobi. Anticancer Chemother."},{"key":"10.1016\/j.antiviral.2019.104678_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/HMER.S130103","article-title":"Grazoprevir\/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy","volume":"10","author":"Sulejmani","year":"2018","journal-title":"Hepat. Med."},{"key":"10.1016\/j.antiviral.2019.104678_bib33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature03580","article-title":"Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase","volume":"435","author":"Tellinghuisen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.104678_bib34","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1099\/jgv.0.001091","article-title":"Limitations of daclatasvir\/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure","volume":"99","author":"Teraoka","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.104678_bib35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","article-title":"Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104678_bib36","first-page":"47","article-title":"Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies","volume":"9","author":"Zhang","year":"2016","journal-title":"N. Am. J. Med. Sci."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:21Z","timestamp":1759062681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219305790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":36,"alternative-id":["S0166354219305790"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104678","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationships of fluorene compounds inhibiting HCV variants","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104678"}}